Back

KAND567, the first selective small molecule CX3CR1 antagonist in clinical development, mediates anti-inflammatory cardioprotective effects in rodent models of atherosclerosis and myocardial infarction

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Emerging treatments in acute coronary syndromes Inflammation ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Ioakim Spyridopoulos

Newcastle University, Newcastle-Upon-Tyne (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
State of the Art - Novel therapies for acute myocardial infarction
Professor G. Heusch (Essen, DE)
Slides Video
Presentation thumbnail
Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 antagonist, in acute myocardial infarction: a randomised open-label phase 2 study
Professor P. Sinnaeve (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Interleukin-1 blockade with Anakinra in ST-segment elevation acute myocardial infarction: Results from the VCUART3 study
Doctor A. Abbate (Charlottesville, US)
Abstract Slides Video

Access the full session

Session thumbnail
Emerging treatments in acute coronary syndromes

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources